SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-126509
Filing Date
2024-05-01
Accepted
2024-05-01 09:07:01
Documents
16
Period of Report
2024-04-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d813637d8k.htm   iXBRL 8-K 32080
2 EX-99.1 d813637dex991.htm EX-99.1 19738
6 GRAPHIC g813637g0501035343425.jpg GRAPHIC 2943
7 GRAPHIC g813637g0501035343793.jpg GRAPHIC 3958
  Complete submission text file 0001193125-24-126509.txt   196989

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pstx-20240430.xsd EX-101.SCH 2837
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pstx-20240430_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pstx-20240430_pre.xml EX-101.PRE 11698
19 EXTRACTED XBRL INSTANCE DOCUMENT d813637d8k_htm.xml XML 3777
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 24900431
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)